FDA Approves MYCOPHENOLATE MOFETIL — Sandoz Inc

Sandoz Inc. has received FDA approval for Mycophenolate Mofetil (ANDA065379) in the oral tablet dosage form, sparking concerns regarding potential revenue erosion and intensified price competition within the immunosuppressant market. The approval of this value-added generic is expected to threaten the market share of patent-protecting leaders by offering a significant cost-saving alternative to brand-name therapies.